% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Qiao:471682,
      author       = {Qiao, Jingxin and Li, Yue-Shan and Zeng, Rui and Liu,
                      Feng-Liang and Luo, Rong-Hua and Huang, Chong and Wang,
                      Yi-Fei and Zhang, Jie and Quan, Baoxue and Shen, Chenjian
                      and Mao, Xin and Liu, Xinlei and Sun, Weining and Yang, Wei
                      and Ni, Xincheng and Wang, Kai and Xu, Ling and Duan, Zi-Lei
                      and Zou, Qing-Cui and Zhang, Hai-Lin and Qu, Wang and Long,
                      Yang-Hao-Peng and Li, Ming-Hua and Yang, Rui-Cheng and Liu,
                      Xiaolong and You, Jing and Zhou, Yangli and Yao, Rui and Li,
                      Wen-Pei and Liu, Jing-Ming and Chen, Pei and Liu, Yang and
                      Lin, Gui-Feng and Yang, Xin and Zou, Jun and Li, Linli and
                      Hu, Yiguo and Lu, Guang-Wen and Li, Wei-Min and Wei, Yu-Quan
                      and Zheng, Yong-Tang and Lei, Jian and Yang, Shengyong},
      title        = {{SARS}-{C}o{V}-2 {M} pro inhibitors with antiviral activity
                      in a transgenic mouse model},
      journal      = {Science},
      volume       = {371},
      number       = {6536},
      issn         = {0036-8075},
      address      = {Cambridge, Mass.},
      publisher    = {Moses King},
      reportid     = {PUBDB-2021-04550},
      pages        = {1374 - 1378},
      year         = {2021},
      abstract     = {Vaccines are an important tool in the fight against
                      COVID-19, but developing antiviral drugs is also a high
                      priority, especially with the rise of variants that may
                      partially evade vaccines. The viral protein main protease is
                      required for cleaving precursor polyproteins into functional
                      viral proteins. This essential function makes it a key drug
                      target. Qiao et al. designed 32 inhibitors based on either
                      boceprevir or telaprevir, both of which are protease
                      inhibitors approved to treat hepatitis C virus. Six
                      compounds protected cells from viral infection with high
                      potency, and two of these were selected for in vivo studies
                      based on pharmokinetic experiments. Both showed strong
                      antiviral activity in a mouse model.},
      cin          = {DOOR ; HAS-User},
      ddc          = {500},
      cid          = {I:(DE-H253)HAS-User-20120731},
      pnm          = {6G3 - PETRA III (DESY) (POF4-6G3)},
      pid          = {G:(DE-HGF)POF4-6G3},
      experiment   = {EXP:(DE-H253)P-P11-20150101},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:33602867},
      UT           = {WOS:000636043400052},
      doi          = {10.1126/science.abf1611},
      url          = {https://bib-pubdb1.desy.de/record/471682},
}